247 related articles for article (PubMed ID: 33095247)
1. Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.
Bomze D; Asher N; Hasan Ali O; Flatz L; Azoulay D; Markel G; Meirson T
JAMA Netw Open; 2020 Oct; 3(10):e2017675. PubMed ID: 33095247
[TBL] [Abstract][Full Text] [Related]
2. The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey.
Evaniew N; Files C; Smith C; Bhandari M; Ghert M; Walsh M; Devereaux PJ; Guyatt G
Spine J; 2015 Oct; 15(10):2188-97. PubMed ID: 26072464
[TBL] [Abstract][Full Text] [Related]
3. Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results.
Khan MS; Fonarow GC; Friede T; Lateef N; Khan SU; Anker SD; Harrell FE; Butler J
JAMA Netw Open; 2020 Aug; 3(8):e2012469. PubMed ID: 32756927
[TBL] [Abstract][Full Text] [Related]
4. Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect.
Horesh N; Bomze D; Lim C; Markel G; Meirson T; Azoulay D
Hepatobiliary Surg Nutr; 2022 Dec; 11(6):861-869. PubMed ID: 36523938
[TBL] [Abstract][Full Text] [Related]
5. The Fragility of Statistically Significant Findings From Randomized Trials in Sports Surgery: A Systematic Survey.
Khan M; Evaniew N; Gichuru M; Habib A; Ayeni OR; Bedi A; Walsh M; Devereaux PJ; Bhandari M
Am J Sports Med; 2017 Jul; 45(9):2164-2170. PubMed ID: 27895038
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
7. Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022).
Sidali S; Sritharan N; Campani C; Gregory J; Durand F; Ganne-Carrié N; Ronot M; Lévy V; Nault JC
JHEP Rep; 2023 Jul; 5(7):100755. PubMed ID: 37425214
[TBL] [Abstract][Full Text] [Related]
8. The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis.
Del Paggio JC; Tannock IF
Lancet Oncol; 2019 Aug; 20(8):1065-1069. PubMed ID: 31296490
[TBL] [Abstract][Full Text] [Related]
9. The Fragility of Statistically Significant Results in Pediatric Orthopaedic Randomized Controlled Trials as Quantified by the Fragility Index: A Systematic Review.
Khormaee S; Choe J; Ruzbarsky JJ; Agarwal KN; Blanco JS; Doyle SM; Dodwell ER
J Pediatr Orthop; 2018 Sep; 38(8):e418-e423. PubMed ID: 29979332
[TBL] [Abstract][Full Text] [Related]
10. Assessing the robustness of negative vascular surgery randomized controlled trials using their reverse fragility index.
Li A; Javidan AP; Liu E; Ahmadvand A; Tam DY; Naji F; Forbes TL
J Vasc Surg; 2023 Jul; 78(1):253-259.e11. PubMed ID: 36572321
[TBL] [Abstract][Full Text] [Related]
11. Calculation of the fragility index of randomized controlled trials in epilepsy published in twelve major journals.
Das S; Xaviar S
Epilepsy Res; 2020 Jan; 159():106258. PubMed ID: 31869724
[TBL] [Abstract][Full Text] [Related]
12. The fragility of significant results from randomized controlled trials in esophageal surgeries.
Lee Y; Samarasinghe Y; Javidan A; Tahir U; Samarasinghe N; Shargall Y; Finley C; Hanna W; Agzarian J
Esophagus; 2023 Apr; 20(2):195-204. PubMed ID: 36689016
[TBL] [Abstract][Full Text] [Related]
13. Are results from randomized trials in anesthesiology robust or fragile? An analysis using the fragility index.
Goerke K; Parke M; Horn J; Meyer C; Dormire K; White B; Bright T; Walters C; Vassar M
Int J Evid Based Healthc; 2020 Mar; 18(1):116-124. PubMed ID: 31415254
[TBL] [Abstract][Full Text] [Related]
14. The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses.
Atal I; Porcher R; Boutron I; Ravaud P
J Clin Epidemiol; 2019 Jul; 111():32-40. PubMed ID: 30940600
[TBL] [Abstract][Full Text] [Related]
15. The Fragility Index in a Cohort of Pediatric Randomized Controlled Trials.
Matics TJ; Khan N; Jani P; Kane JM
J Clin Med; 2017 Aug; 6(8):. PubMed ID: 28805717
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
17. Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis.
Huang X; Chen B; Thabane L; Adachi JD; Li G
Osteoporos Int; 2021 Sep; 32(9):1713-1723. PubMed ID: 33595680
[TBL] [Abstract][Full Text] [Related]
18. The Fragility Index in Hand Surgery Randomized Controlled Trials.
Ruzbarsky JJ; Khormaee S; Daluiski A
J Hand Surg Am; 2019 Aug; 44(8):698.e1-698.e7. PubMed ID: 30420197
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Fragility Index in Cardiovascular Randomized Controlled Trials.
Khan MS; Ochani RK; Shaikh A; Usman MS; Yamani N; Khan SU; Murad MH; Mandrola J; Doukky R; Krasuski RA
Circ Cardiovasc Qual Outcomes; 2019 Dec; 12(12):e005755. PubMed ID: 31822121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
